Serina Therapeutics, Inc. Proceeds from Convertible Debt
Serina Therapeutics, Inc. (SER) reported Proceeds from Convertible Debt of $4.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-03-25
- Serina Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2025-12-31 was $0.00.
- Serina Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2024-12-31 was $0.00.
- Serina Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2023-12-31 was $0.00.
- Serina Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2023-09-30 was $0.00.
- Serina Therapeutics, Inc. proceeds from convertible debt for fiscal 2025 was $4.91M.
- Serina Therapeutics, Inc. proceeds from convertible debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Serina Therapeutics, Inc. proceeds from convertible debt for fiscal 2023 was $10.10M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.91M 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $4.91M 10-Q · filed 2025-11-13 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 derived: sum of 2 quarters · filed 2025-03-24 | $0.00 derived: sum of 3 quarters · filed 2025-03-24 | $10.10M 10-K · filed 2025-03-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $10.10M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $10.10M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $10.10M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |